Compare · ABOS vs MRNA
ABOS vs MRNA
Side-by-side comparison of Acumen Pharmaceuticals Inc. (ABOS) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABOS and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $93.61B, about 5882.9x ABOS ($15.9M).
- MRNA has been more active in the news (15 items in the past 4 weeks vs 11 for ABOS).
- MRNA has more recent analyst coverage (25 ratings vs 14 for ABOS).
- Company
- Acumen Pharmaceuticals Inc.
- Moderna Inc.
- Price
- -
- -
- Market cap
- $15.9M
- $93.61B
- 1M return
- -
- +2.57%
- 1Y return
- -
- +827.07%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 11
- 15
- Recent ratings
- 14
- 25
Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest ABOS
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits
- Acumen Pharmaceuticals downgraded by BofA Securities with a new price target
- Acumen Pharmaceuticals downgraded by Stifel with a new price target
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
- SEC Form EFFECT filed by Acumen Pharmaceuticals Inc.
- SEC Form S-3 filed by Acumen Pharmaceuticals Inc.
- SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.
- SEC Form 8-K filed by Acumen Pharmaceuticals Inc.
- Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Latest MRNA
- Moderna Outlines Next Phase of Growth at Analyst Day
- Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
- Moderna to Present at Upcoming Conference in November 2026
- Chief Operating Officer Andres Juan was granted 7,898 stock options and was granted 16,955 restricted stock units (SEC Form 4)
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study